MTOR and epidermolysis bullosa: Attempts to reverse the PIK3CAH1047R/H1047R EB phenotype with the p110α inhibitor BYL719 were unsuccessful due to poor EB survival in the presence of the drug, consistent with previous studies demonstrating high EB sensitivity to PI3K/mTOR inhibition (40, –42).